Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy

American Journal of Cardiology

Volumn 86, Issue 1, 2000, Pages 46-52

  Blair, Steven N ^a   Capuzzi, David M ^b   Gottlieb, Sidney O ^c   Nguyen, Tu ^d   Morgan, John M ^b   Cater, Nilo B ^e  

^a Cooper Institute ^*  (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Midatlantic Cardiovascular Associates   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARGARINE; MEVINOLIN; PHYTOSTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN; SITOSTANOL; SITOSTEROL; STATINE DERIVATIVE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MARGARINE; MIDDLE AGED; PRAVASTATIN; PYRROLES; SIMVASTATIN; SITOSTEROLS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0034237228     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)00976-0     Document Type: Article

References (21)

1. Cater N.B. Historical and scientific basis for the development of plant stanol ester foods as cholesterol-lowering agents. Eur Heart J. 1:1999;S36-S44.
2. Miettinen T.A., Puska P., Gylling H., Vanhanen H., Vartiainen E. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med. 333:1995;1308-1312.
3. Jones P.J.H., MacDougall D.E., Ntanios F., Vanstone C.A. Dietary phytosterols as cholesterol-lowering agents in humans. Can J Physiol Pharmacol. 75:1997;217-227.
4. Gylling H., Miettinen T.A. Serum cholesterol and cholesterol and lipoprotein metabolism in hypercholesterolaemic NIDDM patients before and during sitostanol ester-margarine treatment. Diabetologia. 37:1994;773-780.
5. Gylling H., Siimes M.A., Miettinen T.A. Sitostanol ester margarine in dietary treatment of children with familial hypercholesterolemia. J Lipid Res. 36:1995;1807-1812.
6. von Bergmann K., Prange W., Dutjohann D. Metabolism and mechanism of action of plant sterols. Eur Heart J. 1:1999;S45-S49.
7. Lutjohann D., von Bergmann K. Phytosterolaemia diagnosis, characterization and therapeutical approaches . Ann Med. 29:1997;181-184.
8. Heinemann T., Axtmann G., von Bergmann K. Comparison of intestinal absorption of cholesterol with different plant sterols in man. Eur J Clin Invest. 23:1993;827-831.
9. Becker M., Staab D., von Bergmann K. Treatment of severe familial hypercholesterolemia in childhood with sitosterol and sitostanol. J Pediatr. 122:1993;292-296.
10. Cater NB, Grundy SM. Lowering serum cholesterol with plant sterols and stanols: historical perspectives. In: Nguyen TT, ed. New Developments in the Dietary Management of High Cholesterol. Postgraduate Medicine Special Report. Minneapolis, MN: McGraw-Hill Health Care Group, 1998:6-14.
11. Mattson F.H., Grundy S.M., Crouse J.R. Optimizing the effect of plant sterols on cholesterol absorption in man. Am J Clin Nutr. 35:1982;697-700.
12. Grundy S.M. Stanol esters as a dietary adjunct to cholesterol-lowering therapies. Eur Heart J. 1:1999;S132-S138.
13. The Lipid Research Clinics coronary primary prevention trial results I. Reduction in the incidence of coronary heart disease . JAMA. 251:1984;351-364.
14. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
15. Dujovne C.A. New lipid lowering drugs and new effects of old drugs. Curr Opin Lipidol. 8:1997;362-368.
16. Bradford R.H., Shear C.L., Chremos A.N., Dujovne C., Downton M., Franklin F.A., Gould A.L., Hesney M., Higgins J., Hurley D.P. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 151:1991;43-49.
17. Jacobson T.A. Improving health outcomes without increasing costs maximizing the full potential of lipid reduction therapy in the primary and secondary prevention of coronary heart disease . Curr Opin Lipidol. 8:1997;369-374.
18. Gylling H., Radhakrishnan R., Miettinen T.A. Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine women and dietary sitostanol . Circulation. 96:1997;4226-4231.
19. Gylling H., Miettinen T.A. Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men. J Lipid Res. 37:1996;1776-1785.
20. Gylling H. Studies of plant stanol esters in different patient populations. Eur Heart J. 1:1999;S109-S113.
21. Puska P. The North Karelia Project: From community intervention to national activity in lowering cholesterol levels and CHD risk. Eur Heart J 1999;1:S9-S13.